Telix Pharmaceuticals Limited
T3X.F
9.55 EUR
1 Tag: N/A
Der Alarm wird direkt gespeichert, ohne auf die Homepage zu springen.
Kursalarme fuer T3X.F
Bitte anmelden, um Kursalarme zu sehen und zu speichern.
Finanzen
Unternehmensinfo
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma; TLX300 for treating soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. In addition, it is developing BiPASS, which is in Phase 3 clinical trial for prostate cancer diagnosis; AlFluor, a novel PET radiochemistry solution; TLX250-Px, a PET diagnostic imaging agent; and TLX101-Px, a radiolabeled amino acid PET agent. It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. The company has strategic collaboration with University Hospital Essen. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
Aktuelle News
-
Cash Flow Stocks With DCF Upside As Higher Bond Yields Test Valuations
Vorschau anzeigen
With European bond yields pushing toward multi year highs on persistent inflation concerns, investors are again paying close attention to what they are actually paying for future cash flows. Higher discount rates tend to punish overhyped stories and highlight companies whose cash generation already looks attractive. This article walks through three stocks from the Undervalued Stocks Based On Cash Flows screener that appear mispriced against their SWS DCF fair values. The three stocks that...
-
Telix Pharmaceuticals Stock Leads 3 Fast Growing Insider Owned Shares
Vorschau anzeigen
Global demand tied to AI related investment is shaping trade and capital flows, and that is putting growth companies with clear earnings ambitions back in focus. Investors are searching for businesses that can convert this demand into real revenue, and management teams that are confident enough to back their own outlook with meaningful share ownership. This article walks through three fast growing stocks with high insider ownership that fit that brief. The three stocks below are just a...
-
Telix Pharmaceuticals Limited Q2 2026 Earnings Call Summary
Vorschau anzeigen
Moby summary of Telix Pharmaceuticals Limited's Q2 2026 earnings call
-
Telix Pharmaceuticals Ltd (TLPPF) (H1 2026) Earnings Call Highlights: Revenue Surges 22% to ...
Vorschau anzeigen
Telix Pharmaceuticals Ltd (TLPPF) reports strong first-half results with EBITDA up 146%, while navigating regulatory hurdles and competitive pressures in the PSMA imaging market.
-
Telix Pharmaceuticals H1 Earnings Call Highlights
Vorschau anzeigen
Telix Pharmaceuticals (NASDAQ:TLX) reported first-half 2026 revenue of $477 million, up 22% from the prior-year period, as demand for its precision medicine imaging products continued to grow. The company said EBITDA increased 146% year over year to $52 million, while net profit after tax rose to $3